CorMedix, Inc. (CRMD) EPS Estimated At $-0.10

August 9, 2018 - By Lisa Delgado

CorMedix, Inc. (NYSEAMERICAN:CRMD) LogoInvestors sentiment decreased to 0.82 in 2018 Q1. Its down 0.43, from 1.25 in 2017Q4. It dropped, as 5 investors sold CorMedix, Inc. shares while 6 reduced holdings. 4 funds opened positions while 5 raised stakes. 3.59 million shares or 3.37% less from 3.71 million shares in 2017Q4 were reported.
Taurus Asset Llc has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Retail Bank Of America De holds 0% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD) for 2,000 shares. Bankshares Of Ny Mellon Corporation has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). California-based Wells Fargo And Mn has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Bnp Paribas Arbitrage Sa holds 0% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD) for 23 shares. 14,006 are owned by Morgan Stanley. Blackrock Incorporated stated it has 557,957 shares or 0% of all its holdings. Vanguard Grp Inc has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Illinois-based Citadel Advsrs Ltd Llc has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Cetera Advsr Llc holds 10,000 shares. State Street Corporation invested 0% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD). 1,500 were accumulated by Tci Wealth Advsrs. Northern invested in 63,401 shares. Geode Cap Limited invested in 295,008 shares or 0% of the stock. Washington invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD).

Analysts expect CorMedix, Inc. (NYSEAMERICAN:CRMD) to report $-0.10 EPS on August, 14 after the close.They anticipate $0.04 EPS change or 28.57 % from last quarter’s $-0.14 EPS. After having $-0.14 EPS previously, CorMedix, Inc.’s analysts see -28.57 % EPS growth. The stock decreased 7.04% or $0.04 during the last trading session, reaching $0.51. About 2.92 million shares traded. CorMedix, Inc. (NYSEAMERICAN:CRMD) has declined 55.43% since August 9, 2017 and is downtrending. It has underperformed by 68.00% the S&P500.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. The company has market cap of $41.77 million. The Company’s primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. It currently has negative earnings. The firm was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.